吉利德科學 GILD 深 滬
等待開盤 09-23 09:30:00 美东时间
152.67
+2.110
+1.40%
華盛通- 最 高153.2807
- 今 開150.645
- 成交量 508.24万股
- 最 低 148.65
- 昨 收 150.56
- 總市值 1893.04亿
- 52周最高 154.83
- 市盈率 靜 22.51
- 換手率 0.41%
- 52周最低 109.16
- 委 比 96.08%
- 總股本 12.40亿
- 歷史最高 154.83
- 量 比 0.64
- 振 幅 3.08%
- 歷史最低 4.26
- 每 手 1
- 風險率 11.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gilead expands voluntary licensing agreements for once-yearly Yeztugo
Gilead Sciences (GILD) is now including its under-development, once-yearly Yeztugo (lenacapavir) for pre-exposure prophylaxis (PrEP) of HIV in its six royalty-free voluntary licensing agreements for t...
09-16 22:13
药物受理最新动态：Gilead Sciences Ireland UC索磷布韦片进口再注册申请获受理
国家药品监督管理局药品审评中心数据显示，2026年9月16日，Gilead Sciences Ireland UC的索磷布韦片申请已获受理，受理号为JYHZ2...
09-16 01:16
Gilead And PAHO Partner To Expand Twice-Yearly Lenacapavir HIV Prevention Access Across Latin America And The Caribbean
– Agreement Establishes a Regional Pathway Through PAHO’s Regional Revolving Funds to Support Country-Led Adoption of Long-Acting HIV Prevention – – Partnership Advances Gilead’s Global Access Strategy, Helping Turn Scientific Innovation into Public Health Impact – Gilead Sciences, Inc. (NASDAQ:GILD...
09-15 23:13
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
INmune Bio Inc. has appointed R. Duane Clark II and James Sapirstein to its Board of Directors to strengthen its commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization. Mr. Clark brings extensive experience in rare-disease commercialization, while Mr. Sapirstein adds expertise in business development and strategic transactions. These appointments aim to enhance market access, pri...
09-14 11:00
9.9亿对赌压顶，勤浩医药港股冲刺背水一战
来源：浩海投研 创新药行业最吊诡的一幕，是一家几乎没有产品收入的公司，也可能在某个季度突然“盈利”。 答案往往不是药卖出去了，而是一笔授权交易（B...
09-13 15:00
内部人交易｜吉利德披露一笔股票增持，金额约3.91万美元
美股上市公司吉利德（GILD）披露一笔内部人股票交易。文件显示，公司内部人Berger (Dietmar P.)（Officer）2026-09-10增持公司股...
09-13 07:01
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175
HSBC analyst Morten Herholdt maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $155 to $175.
09-10 21:55
非农爆表后CPI接棒！9月加息迎“决胜局”，华尔街却押出两套相反剧本？高盛称黄金或迎“入场窗口”
非农爆表后加息预期重燃！美国8月CPI成议息会议前“最后变量”，华尔街却押出两套相反剧本？高盛称黄金或迎“入场窗口”>>
09-09 21:05
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
Assembly Biosciences has exercised its option to share 40% of U.S. development costs and profits for its HSV helicase-primase inhibitor program for recurrent genital herpes under its collaboration with Gilead. Gilead retains sole responsibility for clinical development and commercialization, while Assembly Bio is eligible for up to $280 million in milestones and royalties. The company expects its cash runway to extend into 2029, including a $75 m...
09-08 20:00
